Comparison of the serum lipidome in patients with abdominal aortic aneurysm and peripheral artery disease

Circulation: Cardiovascular Genetics

Volumn 7, Issue 1, 2014, Pages 71-79

  Moxon, Joseph V ^a   Liu, Dawei ^a   Wong, Gerard ^a,b   Weir, Jacquelyn M ^b   Behl Gilhotra, Ratnesh ^a   Bradshaw, Barbara ^a   Kingwell, Bronwyn A ^b   Meikle, Peter J ^b   Golledge, Jonathan ^a,b,c  

^a JAMES COOK UNIVERSITY   (Australia)

^b BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^c TOWNSVILLE HOSPITAL   (Australia)

Author keywords

Aortic aneurysm abdominal; Biomarkers; Lipids; Peripheral arterial disease

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; C REACTIVE PROTEIN; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIACYLGLYCEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LINOLEIC ACID; LIPIDOME; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PHOSPHATIDYLGLYCEROL; SPHINGOSINE 1 PHOSPHATE; TRIACYLGLYCEROL;

ABDOMINAL AORTA ANEURYSM; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; LIPID ANALYSIS; LIPID BLOOD LEVEL; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TANDEM MASS SPECTROMETRY; TRIACYLGLYCEROL BLOOD LEVEL;

AORTIC ANEURYSM, ABDOMINAL; BIOMARKERS; LIPIDS; PERIPHERAL ARTERIAL DISEASE;

AGED; AORTIC ANEURYSM, ABDOMINAL; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIGLYCERIDES; FEMALE; HUMANS; LIPIDS; LOGISTIC MODELS; LYSOPHOSPHOLIPIDS; MALE; MIDDLE AGED; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; RISK FACTORS; ROC CURVE; SPHINGOSINE; TANDEM MASS SPECTROMETRY; TRIGLYCERIDES;

EID: 84898748424     PISSN: 1942325X     EISSN: 19423268     Source Type: Journal    
DOI: 10.1161/CIRCGENETICS.113.000343     Document Type: Article

References (36)

1. Moxon JV, Parr A, Emeto TI, Walker P, Norman PE, Golledge J. Diagnosis and monitoring of abdominal aortic aneurysm: Current status and future prospects. Curr Probl Cardiol. 2010;35:512-548.
2. Bobadilla JL, Kent KC. Screening for abdominal aortic aneurysms. Adv Surg. 2012;46:101-109.
3. Earnshaw JJ. Triumphs and tribulations in a new national screening programme for abdominal aortic aneurysm. Acta Chir Belg. 2012;112: 108-110.
4. Golledge J, Norman PE. Atherosclerosis and abdominal aortic aneurysm: Cause, response, or common risk factors? Arterioscler Thromb Vasc Biol. 2010;30:1075-1077.
5. Golledge J, Norman PE. Current status of medical management for abdominal aortic aneurysm. Atherosclerosis. 2011;217:57-63.
6. Naydeck BL, Sutton-Tyrrell K, Schiller KD, Newman AB, Kuller LH. Prevalence and risk factors for abdominal aortic aneurysms in older adults with and without isolated systolic hypertension. Am J Cardiol. 1999;83:759-764.
7. Singh K, Bønaa KH, Jacobsen BK, Bjørk L, Solberg S. Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study: The Tromsø Study. Am J Epidemiol. 2001;154:236-244.
8. Hobbs SD, Claridge MW, Quick CR, Day NE, Bradbury AW, Wilmink AB. LDL cholesterol is associated with small abdominal aortic aneurysms. Eur J Vasc Endovasc Surg. 2003;26:618-622.
9. Wanhainen A, Bergqvist D, Boman K, Nilsson TK, Rutegård J, Björck M. Risk factors associated with abdominal aortic aneurysm: A population- based study with historical and current data. J Vasc Surg. 2005;41:390-396.
10. Golledge J, Tsao PS, Dalman RL, Norman PE. Circulating markers of abdominal aortic aneurysm presence and progression. Circulation. 2008;118:2382-2392.
11. Didangelos A, Stegemann C, Mayr M. The omics era: proteomics and lipidomics in vascular research. Atherosclerosis. 2012;221:12-17.
12. Meikle PJ, Wong G, Tsorotes D, Barlow CK, Weir JM, Christopher MJ, et al. Plasma lipidomic analysis of stable and unstable coronary artery disease. Arterioscler Thromb Vasc Biol. 2011;31:2723-2732.
13. Ferguson CD, Clancy P, Bourke B, Walker PJ, Dear A, Buckenham T, et al. Association of statin prescription with small abdominal aortic aneurysm progression. Am Heart J. 2010;159:307-313.
14. Golledge J, Clancy P, Jamrozik K, Norman PE. Obesity, adipokines, and abdominal aortic aneurysm: Health in Men study. Circulation. 2007;116:2275-2279.
15. Jayalath RW, Jackson P, Golledge J. Quantification of abdominal aortic calcification on CT. Arterioscler Thromb Vasc Biol. 2006;26: 429-430.
16. Kononenko I, Simec E, Robnik-Sikonja M. Overcoming the myopia of inductive learning algorithms with ReliefF. Appl Intel. 1997;7:39-55.
17. Golledge J, van Bockxmeer F, Jamrozik K, McCann M, Norman PE. Association between serum lipoproteins and abdominal aortic aneurysm. Am J Cardiol. 2010;105:1480-1484.
18. Krishna SM, Seto SW, Moxon JV, Rush C, Walker PJ, Norman PE, et al. Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model. Am J Pathol. 2012;181:706-718.
19. Schubl S, Tsai S, Ryer EJ, Wang C, Hu J, Kent KC, et al. Upregulation of protein kinase cdelta in vascular smooth muscle cells promotes inflammation in abdominal aortic aneurysm. J Surg Res. 2009;153:181-187.
20. Morgan S, Yamanouchi D, Harberg C, Wang Q, Keller M, Si Y, et al. Elevated protein kinase C-δ contributes to aneurysm pathogenesis through stimulation of apoptosis and inflammatory signaling. Arterioscler Thromb Vasc Biol. 2012;32:2493-2502.
21. Liu YM, Wang X, Nawaz A, Kong ZH, Hong Y, Wang CH, et al. Wogonin ameliorates lipotoxicity-induced apoptosis of cultured vascular smooth muscle cells via interfering with DAG-PKC pathway. Acta Pharmacol Sin. 2011;32:1475-1482.
22. Verrier E, Wang L, Wadham C, Albanese N, Hahn C, Gamble JR, et al. PPAR-gamma agonists ameliorate endothelial cell activation via inhibition of diacylglycerol-protein kinase C signaling pathway. Role of diacylglycerol kinase. Circ Res. 2004;94:1515-1522.
23. Golledge J, Cullen B, Rush C, Moran CS, Secomb E, Wood F, et al. Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm. Atherosclerosis. 2010;210:51-56.
24. Nitenberg A, Cosson E, Pham I. Postprandial endothelial dysfunction: Role of glucose, lipids and insulin. Diabetes Metab. 2006;32(Spec No 2):2S28-2S33.
25. Talayero BG, Sacks FM. The role of triglycerides in atherosclerosis. Curr Cardiol Rep. 2011;13:544-552.
26. Goldberg IJ, Eckel RH, McPherson R. Triglycerides and heart disease: Still a hypothesis? Arterioscler Thromb Vasc Biol. 2011;31:1716-1725.
27. Yetukuri L, Söderlund S, Koivuniemi A, Seppänen-Laakso T, Niemelä PS, Hyvönen M, et al. Composition and lipid spatial distribution of HDL particles in subjects with low and high HDL-cholesterol. J Lipid Res. 2010;51:2341-2351.
28. Barter PJ. Hugh sinclair lecture: The regulation and remodelling of HDL by plasma factors. Atheroscler Suppl. 2002;3:39-47.
29. Lamarche B, Uffelman KD, Carpentier A, Cohn JS, Steiner G, Barrett PH, et al. Triglyceride enrichment of HDL enhances in vivo metabolic clearance of HDL apo A-I in healthy men. J Clin Invest. 1999;103:1191-1199.
30. Moxon JV, Padula MP, Clancy P, Emeto TI, Herbert BR, Norman PE, et al. Proteomic analysis of intra-arterial thrombus secretions reveals a negative association of clusterin and thrombospondin-1 with abdominal aortic aneurysm. Atherosclerosis. 2011;219:432-439.
31. Grenon SM, Hughes-Fulford M, Rapp J, Conte MS. Polyunsaturated fatty acids and peripheral artery disease. Vasc Med. 2012;17:51-63.
32. Fei J, Cook C, Gillespie M, Yu B, Fullen K, Santanam N. Atherogenic ω-6 Lipids Modulate PPAR- EGR-1 Crosstalk in Vascular Cells. PPAR Res. 2011;2011:753917.
33. Fei J, Cook C, Santanam N. ω-6 lipids regulate PPAR turnover via reciprocal switch between PGC-1 alpha and ubiquitination. Atherosclerosis. 2012;222:395-401.
34. Ciborowski M, Martin-Ventura JL, Meilhac O, Michel JB, Ruperez FJ, Tuñon J, et al. Metabolites secreted by human atherothrombotic aneurysms revealed through a metabolomic approach. J Proteome Res. 2011;10:1374-1382.
35. Ciborowski M, Teul J, Martin-Ventura JL, Egido J, Barbas C. Metabolomics with LC-QTOF-MS permits the prediction of disease stage in aortic abdominal aneurysm based on plasma metabolic fingerprint. PLoS One. 2012;7:e31982.
36. Takigawa M, Yoshimuta T, Akutsu K, Takeshita S, Yokoyama N. Prevalence and predictors of coexistent silent atherosclerotic cardiovascular disease in patients with abdominal aortic aneurysm without previous symptomatic cardiovascular diseases. Angiology. 2012;63:380-385.